Leerink Swann set a $112.00 price target on Gilead Sciences Inc. (NASDAQ:GILD) in a research note issued to investors on Thursday. The firm currently has a a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also commented on the company. Piper Jaffray Cos. reiterated a buy rating and set a $108.00 price objective on shares of Gilead Sciences in a report on Monday, August 15th. Jefferies Group raised Gilead Sciences from a hold rating to a buy rating and upped their target price for the company from $76.89 to $91.00 in a research report on Tuesday, September 6th. Morgan Stanley reissued a hold rating and issued a $103.00 target price on shares of Gilead Sciences in a research report on Wednesday, June 15th. Berenberg Bank started coverage on Gilead Sciences in a research report on Thursday, September 22nd. They issued a buy rating on the stock. Finally, Maxim Group reissued a hold rating on shares of Gilead Sciences in a research report on Sunday, July 10th. Nine investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $105.26.
Gilead Sciences (NASDAQ:GILD) opened at 80.62 on Thursday. Gilead Sciences has a 12 month low of $76.67 and a 12 month high of $111.11. The stock has a market capitalization of $106.39 billion, a P/E ratio of 7.08 and a beta of 1.06. The stock has a 50 day moving average price of $79.46 and a 200 day moving average price of $85.79.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the prior year, the business posted $3.15 EPS. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. Equities analysts predict that Gilead Sciences will post $11.76 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.33%. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total value of $409,200.00. Following the completion of the transaction, the executive vice president now owns 132,964 shares in the company, valued at $10,881,773.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $83.12, for a total transaction of $166,240.00. Following the completion of the transaction, the executive vice president now owns 63,122 shares of the company’s stock, valued at approximately $5,246,700.64. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of GILD. Nexus Investment Management Inc. increased its position in Gilead Sciences by 4.4% in the first quarter. Nexus Investment Management Inc. now owns 198,850 shares of the biopharmaceutical company’s stock valued at $18,266,000 after buying an additional 8,300 shares during the period. DnB Asset Management AS increased its position in Gilead Sciences by 99.4% in the first quarter. DnB Asset Management AS now owns 231,282 shares of the biopharmaceutical company’s stock valued at $21,246,000 after buying an additional 115,300 shares during the period. Denali Advisors LLC acquired a new position in Gilead Sciences during the first quarter valued at approximately $1,920,000. Lau Associates LLC increased its position in Gilead Sciences by 0.7% in the first quarter. Lau Associates LLC now owns 29,400 shares of the biopharmaceutical company’s stock valued at $2,701,000 after buying an additional 200 shares during the period. Finally, CENTRAL TRUST Co acquired a new position in Gilead Sciences during the first quarter valued at approximately $10,862,000. Institutional investors and hedge funds own 77.94% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.